Literature DB >> 1418862

Increased binding of 3H-L-deprenyl in spinal cords from patients with amyotrophic lateral sclerosis as demonstrated by autoradiography.

S M Aquilonius1, S S Jossan, J G Ekblom, H Askmark, P G Gillberg.   

Abstract

The present investigation has applied quantitative autoradiography and histochemistry to study the regional distribution of MAO-B and its relation to the number of cells in respective regions. L-deprenyl binds irreversibly and quantitatively to the B-form of monoamine oxidase, MAO, and is an ideal 3H-ligand to measure the MAO-B enzyme protein in tissues by means of in vitro autoradiography. The investigation is performed on spinal sections from five controls and five cases with amyotrophic lateral sclerosis (ALS) on cervical, thoracic and lumbar level. The highest density of 3H-L-deprenyl binding was found around the central canal (lamina X). MAO-B was markedly increased (up to 2.5 times of values in controls) specifically in regions of neurodegeneration e.g. motor neuron laminae and corticospinal tracts. There was a high correlation between glial cell count and 3H-L-deprenyl binding with a relation indicating enhanced MAO-B protein in glial cells within areas of neurodegeneration. In contrast the increased microglial cell number in ALS did not show any correlation with 3H-L-deprenyl binding.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1418862     DOI: 10.1007/bf01245357

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  28 in total

1.  Expression of monoamine oxidase B activity in astrocytes of senile plaques.

Authors:  S Nakamura; T Kawamata; I Akiguchi; M Kameyama; N Nakamura; H Kimura
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

2.  Monoamine oxidase B in brains from patients with Alzheimer's disease: a biochemical and autoradiographical study.

Authors:  S S Jossan; P G Gillberg; C G Gottfries; I Karlsson; L Oreland
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

3.  Large-section cryomicrotomy for in vitro receptor autoradiography.

Authors:  P G Gillberg; S S Jossan; H Askmark; S M Aquilonius
Journal:  J Pharmacol Methods       Date:  1986-04

4.  cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties.

Authors:  A W Bach; N C Lan; D L Johnson; C W Abell; M E Bembenek; S W Kwan; P H Seeburg; J C Shih
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

5.  Dopamine is a monoamine oxidase B substrate in man.

Authors:  V Glover; M Sandler; F Owen; G J Riley
Journal:  Nature       Date:  1977-01-06       Impact factor: 49.962

6.  Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type.

Authors:  L Oreland; C G Gottfries
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1986       Impact factor: 5.067

7.  The effect of age on the activity and molecular properties of human brain monoamine oxidase.

Authors:  C J Fowler; A Wiberg; L Oreland; J Marcusson; B Winblad
Journal:  J Neural Transm       Date:  1980       Impact factor: 3.575

8.  Rate of cell death in parkinsonism indicates active neuropathological process.

Authors:  P L McGeer; S Itagaki; H Akiyama; E G McGeer
Journal:  Ann Neurol       Date:  1988-10       Impact factor: 10.422

9.  Quantitative localization of human brain monoamine oxidase B by large section autoradiography using L-[3H]deprenyl.

Authors:  S S Jossan; P G Gillberg; R d'Argy; S M Aquilonius; B Långström; C Halldin; L Oreland
Journal:  Brain Res       Date:  1991-04-26       Impact factor: 3.252

10.  [Monoamine oxidase activity in brain regions and organs of patients with Parkinson's disease and Huntington's disease and serum MAO activity of patients with Huntington's disease as compared with neurologically healthy individuals (author's transl)].

Authors:  G Schneider; H Oepen; H R von Wedel
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1981
View more
  9 in total

Review 1.  Treatment of amyotrophic lateral sclerosis.

Authors:  A Eisen; M Weber
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

Review 2.  Amyotrophic lateral sclerosis: current and future treatment strategies.

Authors:  B W Festoff
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 3.  Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks.

Authors:  Stefanie M A Willekens; Donatienne Van Weehaeghe; Philip Van Damme; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-08       Impact factor: 9.236

Review 4.  Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia.

Authors:  William C Kreisl; Ioline D Henter; Robert B Innis
Journal:  Adv Pharmacol       Date:  2017-11-10

Review 5.  Neuroinflammation in Neurodegenerative Disorders-a Review.

Authors:  Martin Schain; William Charles Kreisl
Journal:  Curr Neurol Neurosci Rep       Date:  2017-03       Impact factor: 5.081

6.  Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset.

Authors:  Angelina Cistaro; Maria Consuelo Valentini; Adriano Chiò; Flavio Nobili; Andrea Calvo; Cristina Moglia; Anna Montuschi; Silvia Morbelli; Dario Salmaso; Piercarlo Fania; Giovanna Carrara; Marco Pagani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-17       Impact factor: 9.236

7.  Growth factor receptors in amyotrophic lateral sclerosis.

Authors:  A Adem; J Ekblom; P G Gillberg
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

8.  Insulin-like growth factor-1 receptors in human spinal cord: changes in amyotrophic lateral sclerosis.

Authors:  A Adem; J Ekblom; P G Gillberg; S S Jossan; A Höög; B Winblad; S M Aquilonius; L H Wang; V Sara
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 9.  Imaging of Reactive Astrogliosis by Positron Emission Tomography.

Authors:  Ryuichi Harada; Shozo Furumoto; Yukitsuka Kudo; Kazuhiko Yanai; Victor L Villemagne; Nobuyuki Okamura
Journal:  Front Neurosci       Date:  2022-02-08       Impact factor: 4.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.